Viapath leads the way in clinical drugs of abuse testing

From today, Monday 2 November 2015, there will be significant changes made to Viapath’s urine drugs of abuse screening service at King’s College Hospital.

The current process of immunoassay screening followed by amfetamine and/or opiate confirmation will be discontinued. Instead our users will receive a single report, with all drugs (apart from cannabinoids, benzodiazepines and barbiturates – which are screened for seperately) analysed using high-resolution mass spectrometry (HR-MS), making the Viapath Drugs of Abuse (DoA) Laboratory at King’s one of the first UK-based clinical laboratories performing routine DoA testing via HR-MS.

This methodology will provide our users with a robust, more accurate platform for testing in the ever changing drug scene.

“This is a significant change for our drugs of abuse screening service. And we hope that this is just the start – the new technology we are using for all samples gives us the analytical capability to make sure our services are always kept up-to-date – something which is key in today’s ever-changing drug scene” – Lewis Couchman, Senior Clinical Scientist and Development Lead

Further information

For more details on the changes taking effect today, please visit our Drugs of Abuse Laboratory page by clicking the link below where you can also find contact details for the laboratory and our updated test repertoire:
Drugs of Abuse Laboratory, Toxicology Department – Viapath at King’s College Hospital

For Business Development enquiries, please contact our Business Development Team using the details below:
BusinessDevelopment [at] viapath [dot] co [dot] uk (subject: Drugs%20of%20Abuse%20testing%20service)
020 7188 7188 ext.54109